Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders
Authors
Keywords
-
Journal
Journal of Comparative Effectiveness Research
Volume 3, Issue 4, Pages 399-422
Publisher
Future Medicine Ltd
Online
2014-10-02
DOI
10.2217/cer.14.34
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Concerns for severity in priority setting in health care: A review of trade-off data in preference studies and implications for societal willingness to pay for a QALY
- (2014) Erik Nord et al. HEALTH POLICY
- An Improved Approach To Measuring Drug Innovation Finds Steady Rates Of First-In-Class Pharmaceuticals, 1987–2011
- (2013) Michael Lanthier et al. HEALTH AFFAIRS
- Development of a supportive care measure for economic evaluation of end-of-life care using qualitative methods
- (2013) Eileen J Sutton et al. PALLIATIVE MEDICINE
- Eliciting Preferences for Prioritizing Treatment of Rare Diseases: the Role of Opportunity Costs and Framing Effects
- (2013) Arna S. Desser et al. PHARMACOECONOMICS
- Statistical Challenges in the Evaluation of Treatments for Small Patient Populations
- (2013) E. L. Korn et al. Science Translational Medicine
- Prioritizing treatment of rare diseases: A survey of preferences of Norwegian doctors
- (2013) Arna S. Desser SOCIAL SCIENCE & MEDICINE
- Ongoing pharmaceutical reforms in France
- (2013) Catherine Sermet et al. Applied Health Economics and Health Policy
- Clinical Pharmacology and Orphan Drugs: An Informational Inventory 2006–2010
- (2012) E D Bashaw et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Raising Orphans: How Clinical Development Programs of Drugs for Rare and Common Diseases Are Different
- (2012) M Orfali et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The Future of Orphan Drug Development
- (2012) J Woodcock CLINICAL PHARMACOLOGY & THERAPEUTICS
- Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU
- (2012) Roberta Joppi et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- SOCIETAL VIEWS ON NICE, CANCER DRUGS FUND AND VALUE-BASED PRICING CRITERIA FOR PRIORITISING MEDICINES: A CROSS-SECTIONAL SURVEY OF 4118 ADULTS IN GREAT BRITAIN
- (2012) Warren G. Linley et al. HEALTH ECONOMICS
- CAN COST-EFFECTIVENESS ANALYSIS INTEGRATE CONCERNS FOR EQUITY? SYSTEMATIC REVIEW
- (2012) Mira Johri et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Rare diseases and orphan drugs
- (2012) Irena Melnikova NATURE REVIEWS DRUG DISCOVERY
- What the Orphan Drug Act Has Done Lately for Children With Rare Diseases: A 10-Year Analysis
- (2012) C. Thorat et al. PEDIATRICS
- An Evaluation Framework for Funding Drugs for Rare Diseases
- (2012) Eric Winquist et al. VALUE IN HEALTH
- Maximising health versus sharing: Measuring preferences for the allocation of the health budget
- (2012) Jeff Richardson et al. SOCIAL SCIENCE & MEDICINE
- A European perspective - the European clinical research infrastructures network
- (2011) J. Demotes-Mainard et al. ANNALS OF ONCOLOGY
- Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts
- (2011) Szymon Jarosławski et al. BMC HEALTH SERVICES RESEARCH
- The National Institute for Health and Clinical Excellence and Its Role in Assessing the Value of New Cancer Treatments in England and Wales
- (2011) R. Trowman et al. CLINICAL CANCER RESEARCH
- Time to revisit the orphan drug law
- (2011) Silvio Garattini EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- The cost of drug development: A systematic review
- (2011) Steve Morgan et al. HEALTH POLICY
- Coverage with evidence development: The Ontario experience
- (2011) Leslie Levin et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Age as a Criterion for Setting Priorities in Health Care? A Survey of the German Public View
- (2011) Adele Diederich et al. PLoS One
- Development of a self-report measure of capability wellbeing for adults: the ICECAP-A
- (2011) Hareth Al-Janabi et al. QUALITY OF LIFE RESEARCH
- A point of minimal important difference (MID): a critique of terminology and methods
- (2011) Madeleine T King Expert Review of Pharmacoeconomics & Outcomes Research
- Review of regulatory recommendations for orphan drug submissions in the netherlands and scotland: focus on the underlying pharmacoeconomic evaluations
- (2010) Stefan Vegter et al. CLINICAL THERAPEUTICS
- Rare diseases, orphan drugs and their regulation: questions and misconceptions
- (2010) Erik Tambuyzer NATURE REVIEWS DRUG DISCOVERY
- Legislating against Use of Cost-Effectiveness Information
- (2010) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013
- (2010) Alain Denis et al. JOURNAL OF MEDICAL ECONOMICS
- Global Spending on Orphan Drugs in France, Germany, the UK, Italy and Spain during 2007
- (2010) Javier Orofino et al. Applied Health Economics and Health Policy
- Orphan drug development is not taking off
- (2009) Roberta Joppi et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI
- (2009) M. Schlander et al. CURRENT MEDICAL RESEARCH AND OPINION
- Translation of rare disease research into orphan drug development: disease matters
- (2009) Harald E. Heemstra et al. DRUG DISCOVERY TODAY
- Factors associated with success of market authorisation applications for pharmaceutical drugs submitted to the European Medicines Agency
- (2009) Jan Regnstrom et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Global Drug Discovery: Europe Is Ahead
- (2009) Donald W. Light HEALTH AFFAIRS
- Drug development costs when financial risk is measured using the Fama-French three-factor model
- (2009) John A. Vernon et al. HEALTH ECONOMICS
- Severity of illness and priority setting in healthcare: A review of the literature
- (2009) Koonal K. Shah HEALTH POLICY
- Comparison of 5 Health-Related Quality-of-Life Indexes Using Item Response Theory Analysis
- (2009) Dennis G. Fryback et al. MEDICAL DECISION MAKING
- QALYs: The Basics
- (2009) Milton C. Weinstein et al. VALUE IN HEALTH
- Enhancing the rational use of new medicines across European health care systems
- (2008) Silvio Garattini et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Should the capability approach be applied in Health Economics?
- (2008) Joanna Coast et al. HEALTH ECONOMICS
- Aversion to health inequalities and priority setting in health care
- (2008) Han Bleichrodt et al. JOURNAL OF HEALTH ECONOMICS
- The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process
- (2008) M Schlander JOURNAL OF MEDICAL ETHICS
- Rare diseases: what's next?
- (2008) Giuseppe Remuzzi et al. LANCET
- Welfarism, extra-welfarism and capability: The spread of ideas in health economics
- (2008) Joanna Coast et al. SOCIAL SCIENCE & MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started